EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Evolus, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.36+0.26 (+3.66%)
Close on Oct 19, 2026
- Market cap
- $485.24M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
84.0%
55M of 66M shares
Institutional holders
158
33 new, 20 sold out
Net institutional buying
10M
In Q2 2026
Insider trades, 12 months
0 buys · 7 sales
Net sold $1.84M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Timothy P. Lynch | 6,425,726 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Wilmot B. Harkey | 5,726,857 | 8.85% | 13G (passive) amendment | Sep 30, 2025 |
| Tang Capital Management, LLC | 4,997,399 | 7.90% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 4,364,896 | 6.90% | 13G (passive) amendment | Dec 31, 2024 |
| Perceptive Life Sciences Master Fund, Ltd. | 4,129,142 | 6.40% | 13G (passive) amendment | Mar 31, 2025 |
| Soleus Capital Management, L.P. | 3,480,000 | 5.30% | 13G (passive) | Aug 27, 2026 |
| Caligan Partners LP | 3,341,970 | 5.20% | 13G (passive) | Jun 30, 2025 |
| Tang Capital Partners, LP | 3,097,399 | 5.40% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EOLS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 11,204,042 | 16.96% | $77.76M | +4,827,185 | 1.29% |
| BlackRock, Inc. | 4,840,828 | 7.33% | $33.60M | +550,445 | 0.00% |
| Braidwell LP | 3,155,209 | 4.78% | $21.90M | +50,000 | 0.81% |
| Frazier Life Sciences Management, L.P. | 2,630,665 | 3.98% | $18.26M | – | 0.40% |
| Perceptive Advisors LLC | 2,459,285 | 3.72% | $17.07M | +1,172,423 | 0.26% |
| Vanguard Capital Management LLC | 2,362,893 | 3.58% | $16.40M | −107,515 | 0.00% |
| Assenagon Asset Management S.A. | 1,816,360 | 2.75% | $12.61M | +1,218,215 | 0.01% |
| Millennium Management LLC | 1,787,929 | 2.71% | $12.41M | +326,770 | 0.00% |
| State Street Corp | 1,697,294 | 2.57% | $11.78M | +376,504 | 0.00% |
| Geode Capital Management, LLC | 1,608,394 | 2.44% | $11.17M | +227,056 | 0.00% |
| Stonepine Capital Management, LLC | 1,590,162 | 2.41% | $11.04M | −168,929 | 6.23% |
| Point72 Asset Management, L.P. | 1,508,518 | 2.28% | $10.47M | New | 0.01% |
| Pinnacle Associates Ltd | 1,487,264 | 2.25% | $10.32M | +328,369 | 0.11% |
| Armistice Capital, LLC | 1,436,000 | 2.17% | $9.97M | +40,000 | 0.12% |
| Rice Hall James & Associates, LLC | 1,289,888 | 1.95% | $8.95M | +35,069 | 0.44% |
| AWH Capital, L.P. | 1,250,000 | 1.89% | $8.68M | +625,000 | 3.01% |
| Goldman Sachs Group Inc | 1,219,419 | 1.85% | $8.46M | +133,021 | 0.00% |
| Soleus Capital Management, L.P. | 822,428 | 1.25% | $5.71M | −1,422,932 | 0.20% |
| Soviero Asset Management, LP | 770,000 | 1.17% | $5.34M | +89,627 | 2.25% |
| UBS Group AG | 752,679 | 1.14% | $5.22M | −202 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 158 | 55M | 84.0% | 33 / 56 | 40 / 20 | 13M | 4M |
| Q1 2026 | 147 | 46M | 69.1% | 27 / 56 | 43 / 45 | 11M | 11M |
| Q4 2025 | 169 | 49M | 74.5% | 41 / 53 | 47 / 31 | 11M | 17M |
| Q3 2025 | 160 | 55M | 83.1% | 24 / 57 | 52 / 36 | 9M | 13M |
| Q2 2025 | 172 | 59M | 88.7% | 28 / 63 | 51 / 34 | 12M | 8M |
| Q1 2025 | 179 | 54M | 82.2% | 31 / 59 | 56 / 15 | 8M | 5M |
| Q4 2024 | 164 | 52M | 78.6% | 26 / 55 | 49 / 25 | 6M | 5M |
| Q3 2024 | 165 | 50M | 76.4% | 31 / 55 | 43 / 21 | 8M | 9M |
| Q2 2024 | 156 | 55M | 83.7% | 26 / 71 | 38 / 33 | 11M | 12M |
| Q1 2024 | 164 | 57M | 85.6% | 31 / 61 | 48 / 17 | 14M | 8M |
| Q4 2023 | 151 | 51M | 77.3% | 28 / 44 | 54 / 14 | 18M | 8M |
| Q3 2023 | 137 | 41M | 62.8% | 15 / 63 | 33 / 13 | 8M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EOLS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,544,992 | 2.34% | $10.72M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,538,195 | 2.33% | $10.68M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 770,279 | 1.17% | $5.35M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 645,689 | 0.98% | $3.77M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 557,657 | 0.84% | $3.87M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 338,034 | 0.51% | $2.22M | 0.01% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 325,329 | 0.49% | $2.26M | 0.53% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 309,043 | 0.47% | $2.03M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 287,795 | 0.44% | $1.89M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 199,442 | 0.30% | $1.38M | 0.09% | Jun 30, 2026 |
| iShares U.S. Pharmaceuticals ETF | 171,630 | 0.26% | $1.19M | 0.10% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 144,427 | 0.22% | $843.45K | 0.01% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 143,338 | 0.22% | $940.30K | 0.00% | May 31, 2026 |
| Clearwater Select Equity Fund | 115,686 | 0.18% | $802.86K | 0.16% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 113,928 | 0.17% | $747.37K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Moatazedi | See Remarks, Director | 499,592 | 0.76% | Sep 4, 2026 |
| Rui Avelar | See Remarks | 427,423 | 0.65% | Mar 20, 2026 |
| Tatjana Mitchell | Chief Financial Officer | 226,092 | 0.34% | Feb 19, 2026 |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer | 89,949 | 0.14% | Aug 26, 2025 |
| Sandra Beaver | Chief Financial Officer | 167,089 | 0.25% | May 14, 2025 |
| Karah Herdman Parschauer | Director | 77,742 | 0.12% | Feb 19, 2026 |
| Brady Stewart | Director | 134,188 | 0.20% | Feb 19, 2026 |
| Albert G. White III | Director | 95,937 | 0.15% | Feb 19, 2026 |
| David N. Gill | Director | 86,887 | 0.13% | Feb 19, 2026 |
| Vikram Malik | Director | 321,109 | 0.49% | Feb 19, 2026 |
| Simone Blank | Director | 559,894 | 0.85% | Mar 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Moatazedi See Remarks, Director | Sep 2, 2026 | Sale | −105,108 | $9.04 | $950.18K | 499,592 |
| David Moatazedi See Remarks, Director | Mar 20, 2026 | Sale(10b5-1 plan) | −13,669 | $4.75 | $64.93K | 604,700 |
| Rui Avelar See Remarks | Mar 20, 2026 | Sale(10b5-1 plan) | −3,119 | $4.75 | $14.82K | 427,423 |
| Rui Avelar See Remarks | Mar 17, 2026 | Sale(10b5-1 plan) | −29,996 | $4.89 | $146.68K | 430,542 |
| David Moatazedi See Remarks, Director | Mar 17, 2026 | Sale(10b5-1 plan) | −116,720 | $4.89 | $570.76K | 618,369 |
| Rui Avelar See Remarks | Mar 16, 2026 | Option exercise | +8,804 | – | – | 460,538 |
| David Moatazedi See Remarks, Director | Mar 16, 2026 | Option exercise | +67,489 | – | – | 735,089 |
| Rui Avelar See Remarks | Feb 17, 2026 | Award | +94,913 | – | – | 451,734 |
| Albert G. White III Director | Feb 17, 2026 | Award | +45,559 | – | – | 95,937 |
| Brady Stewart Director | Feb 17, 2026 | Award | +45,559 | – | – | 134,188 |
| Tatjana Mitchell Chief Financial Officer | Feb 17, 2026 | Award | +121,489 | – | – | 226,092 |
| David Moatazedi See Remarks, Director | Feb 17, 2026 | Award | +313,212 | – | – | 667,600 |
| David N. Gill Director | Feb 17, 2026 | Award | +45,559 | – | – | 86,887 |
| Karah Herdman Parschauer Director | Feb 17, 2026 | Award | +45,559 | – | – | 77,742 |
| Vikram Malik Director | Feb 17, 2026 | Award | +45,559 | – | – | 321,109 |
| Rui Avelar See Remarks | Dec 22, 2025 | Sale(10b5-1 plan) | −2,261 | $7.15 | $16.17K | 356,821 |
| David Moatazedi See Remarks, Director | Dec 22, 2025 | Sale(10b5-1 plan) | −10,539 | $7.15 | $75.35K | 354,388 |
| Tatjana Mitchell Chief Financial Officer | Sep 8, 2025 | Award | +104,603 | – | – | 104,603 |
| Tomoko Yamagishi-Dressler Chief Marketing Officer | Aug 22, 2025 | Sale(10b5-1 plan) | −5,722 | $7.51 | $42.97K | 89,949 |
| Brady Stewart Director | Aug 15, 2025 | Buy | +30,000 | $6.82 | $204.60K | 88,629 |
| David Moatazedi See Remarks, Director | Jun 16, 2025 | Sale | −16,582 | $9.89 | $164.00K | 364,927 |
| David Moatazedi See Remarks, Director | Jun 13, 2025 | Sale | −111,323 | $10.05 | $1.12M | 381,509 |
| Albert G. White III Director | Jun 9, 2025 | Buy | +20,000 | $9.45 | $189.00K | 50,378 |
| Sandra Beaver Chief Financial Officer | May 13, 2025 | Sale(10b5-1 plan) | −6,494 | $10.02 | $65.07K | 167,089 |
| Rui Avelar See Remarks | May 12, 2025 | Sale(10b5-1 plan) | −3,385 | $9.87 | $33.41K | 359,082 |
| David Moatazedi See Remarks, Director | May 12, 2025 | Sale(10b5-1 plan) | −15,787 | $9.87 | $155.82K | 492,832 |
| David Moatazedi See Remarks, Director | Mar 27, 2025 | Sale(10b5-1 plan) | −6,251 | $12.40 | $77.51K | 508,619 |
| David Moatazedi See Remarks, Director | Mar 18, 2025 | Sale(10b5-1 plan) | −103,376 | $13.26 | $1.37M | 514,870 |
| Sandra Beaver Chief Financial Officer | Mar 18, 2025 | Sale(10b5-1 plan) | −8,996 | $13.26 | $119.29K | 173,583 |
| Tomoko Yamagishi-Dressler Chief Marketing Officer | Mar 18, 2025 | Sale(10b5-1 plan) | −4,536 | $13.26 | $60.15K | 95,671 |
| Rui Avelar See Remarks | Mar 18, 2025 | Sale(10b5-1 plan) | −27,904 | $13.26 | $370.01K | 362,467 |
| Karah Herdman Parschauer Director | Mar 12, 2025 | Sale | −12,888 | $12.99 | $167.42K | 32,183 |
| Brady Stewart Director | Mar 7, 2025 | Award | +7,364 | – | – | 58,629 |
| David Moatazedi See Remarks, Director | Mar 7, 2025 | Award | +95,399 | – | – | 618,246 |
| Rui Avelar See Remarks | Mar 7, 2025 | Award | +23,776 | – | – | 390,371 |
| Sandra Beaver Chief Financial Officer | Mar 7, 2025 | Award | +35,663 | – | – | 182,579 |
| Vikram Malik Director | Mar 7, 2025 | Award | +7,364 | – | – | 253,878 |
| Tomoko Yamagishi-Dressler Chief Marketing Officer | Mar 7, 2025 | Award | +17,832 | – | – | 100,207 |
| Simone Blank Director | Mar 7, 2025 | Award | +7,364 | – | – | 77,111 |
| Karah Herdman Parschauer Director | Mar 7, 2025 | Award | +7,364 | – | – | 45,071 |
| Albert G. White III Director | Mar 7, 2025 | Award | +7,364 | – | – | 30,378 |
| David N. Gill Director | Mar 7, 2025 | Award | +7,364 | – | – | 41,328 |
| Rui Avelar See Remarks | Dec 23, 2024 | Sale(10b5-1 plan) | −2,252 | $10.85 | $24.43K | 366,595 |
| David Moatazedi See Remarks, Director | Dec 23, 2024 | Sale(10b5-1 plan) | −10,502 | $10.85 | $113.95K | 522,847 |
| Sandra Beaver Chief Financial Officer | Dec 23, 2024 | Sale(10b5-1 plan) | −1,586 | $10.85 | $17.21K | 146,916 |
| Sandra Beaver Chief Financial Officer | Sep 6, 2024 | Sale | −3,276 | $14.98 | $49.07K | 148,502 |
| Tomoko Yamagishi-Dressler Chief Marketing Officer | Aug 30, 2024 | Sale | −5,631 | $15.85 | $89.25K | 82,375 |
| Albert G. White III Director | Jul 1, 2024 | Award | +23,014 | – | – | 23,014 |
| David Moatazedi See Remarks, Director | Jun 6, 2024 | Sale | −175,940 | $12.59 | $2.22M | 533,349 |
| David Moatazedi See Remarks, Director | Jun 6, 2024 | Option exercise | +175,940 | $7.28 | $1.28M | 709,289 |
| David Moatazedi See Remarks, Director | Jun 5, 2024 | Option exercise | +155,278 | $5.46 | $847.82K | 688,627 |
| David Moatazedi See Remarks, Director | Jun 5, 2024 | Sale | −155,278 | $12.92 | $2.01M | 533,349 |
| David Moatazedi See Remarks, Director | Jun 4, 2024 | Sale | −140,214 | $12.73 | $1.78M | 533,349 |
| Vikram Malik Director | Jun 3, 2024 | Sale | −7,500 | $12.96 | $97.20K | 246,514 |
| David N. Gill Director | May 14, 2024 | Sale | −6,718 | $12.60 | $84.65K | 33,964 |
| Vikram Malik Director | May 13, 2024 | Sale | −28,000 | $12.93 | $362.04K | 254,014 |
| David N. Gill Director | May 13, 2024 | Sale | −3,643 | $12.72 | $46.34K | 40,682 |
| Rui Avelar See Remarks | May 10, 2024 | Sale | −3,441 | $12.72 | $43.77K | 368,847 |
| David Moatazedi See Remarks, Director | May 10, 2024 | Sale | −16,051 | $12.72 | $204.17K | 673,563 |
| Sandra Beaver Chief Financial Officer | May 10, 2024 | Sale | −2,423 | $12.72 | $30.82K | 151,778 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Moatazedi David Officer, Director | Sep 2, 2026 | 105,108 | $950.02K | Sep 2, 2026 | Performance Shares |
| Moatazedi David Officer, Director | Jun 16, 2025 | 16,582 | $164.05K | Jun 16, 2025 | Performance Shares |
| Moatazedi David Officer, Director | Jun 13, 2025 | 111,323 | $1.12M | Jun 13, 2025 | Restricted Stock |
| Karah Herdman Parschauer Director | Mar 12, 2025 | 12,888 | $167.47K | Mar 12, 2025 | RESTRICTED STOCK |
| David Moatazedi Officer | Jun 6, 2024 | 200,000 | $2.54M | Jun 6, 2024 | STOCK OPTION EXERCISE |
| David Moatazedi Officer | Jun 5, 2024 | 155,278 | $1.97M | Jun 5, 2024 | STOCK OPTION EXERCISE |
| David Moatazedi Officer | Jun 4, 2024 | 140,214 | $1.78M | Jun 4, 2024 | RESTRICTED STOCK |
| Vikram Malik Officer | Jun 3, 2024 | 7,500 | $97.20K | Jun 3, 2024 | RETAIL PURCHASE |
| Vikram Malik Director | May 14, 2024 | 28,000 | $362.04K | May 13, 2024 | RETAIL SHARES |
| David N. Gill Director | May 13, 2024 | 10,361 | $131.58K | May 13, 2024 | RESTRICTED STOCK |
| Parschauer Karah Director | Jan 30, 2024 | 11,931 | $156.73K | Jan 30, 2024 | Restricted Stock |
| David Moatazedi Officer | Dec 6, 2023 | 82,648 | $826.48K | Dec 6, 2023 | RESTRICTED STOCK |